{
  "guideline": {
    "id": "PA166182843",
    "name": "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
    "source": "DPWG",
    "version": 12,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182843",
    "relatedChemicals": [
      {
        "id": "PA448500",
        "name": "atorvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299128",
      "name": "Recommendation PA166299128",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061491,
        "html": "<p>The guideline does not provide a recommendation for atorvastatin in patients with the <em>SLCO1B1</em> 521 TT genotype</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of the _SLCO1B1_ 521 TT genotype on atorvastatin."
      ],
      "lookupKey": {
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299127",
      "name": "Recommendation PA166299127",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061490,
        "html": "<ul>\n<li>Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Choose an alternative.\nDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n<li>If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n<ul>\n<li>Patient has NO additional significant risk factors for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n"
      },
      "implications": [
        "The risk of myopathy may be increased. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase the atorvastatin plasma concentration."
      ],
      "lookupKey": {
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299126",
      "name": "Recommendation PA166299126",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061489,
        "html": "<ul>\n<li>Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Choose an alternative.\nRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n<li>If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n<ul>\n<li>Patient has NO additional significant risk factors for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n"
      },
      "implications": [
        "The risk of myopathy can be elevated. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase atorvastatin plasma concentrations."
      ],
      "lookupKey": {
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-25-16-13"
}